Tremelimumab and Imfinzi Combo Effective for MesotheliomaResearch & Clinical Trials
Asbestos.com is the nation’s most trusted mesothelioma resource
The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.
Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.
More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.
About The Mesothelioma Center at Asbestos.com
- Assisting mesothelioma patients and their loved ones since 2006.
- Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
- A+ rating from the Better Business Bureau.
- 5-star reviewed mesothelioma and support organization.
"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."LashawnMesothelioma patient’s daughter
How to Cite Asbestos.com’s Article
Povtak, T. (2021, August 19). Tremelimumab and Imfinzi Combo Effective for Mesothelioma. Asbestos.com. Retrieved October 6, 2022, from https://www.asbestos.com/news/2018/06/20/tremelimumab-imfinzi-effective-mesothelioma/
Povtak, Tim. "Tremelimumab and Imfinzi Combo Effective for Mesothelioma." Asbestos.com, 19 Aug 2021, https://www.asbestos.com/news/2018/06/20/tremelimumab-imfinzi-effective-mesothelioma/.
Povtak, Tim. "Tremelimumab and Imfinzi Combo Effective for Mesothelioma." Asbestos.com. Last modified August 19, 2021. https://www.asbestos.com/news/2018/06/20/tremelimumab-imfinzi-effective-mesothelioma/.
The novel immunotherapy drug mixture of tremelimumab and Imfinzi (durvalumab) produced encouraging results in the first phase II mesothelioma clinical trial examining this combination.
The study, which included 40 mesothelioma patients in Italy, was published in the June 2018 edition of The Lancet Respiratory Medicine.
Similar — or even more promising — results with this combination are expected to follow soon in the United States.
“Results from this study are very promising,” investigator Dr. Luana Calabro, Siena University Hospital, told Asbestos.com. “This regimen also has shown a good safety profile. It warrants further investigation in a large population of mesothelioma patients.”
More Tremelimumab and Imfinzi Studies Progressing
The two-drug combination for pleural mesothelioma is being studied at the Dana-Farber Cancer Institute in Boston and the Baylor College of Medicine in Houston.
Both clinical trials are still recruiting new patients.
The trial at Baylor is studying the use of the immunotherapy combination in conjunction with aggressive surgery. The study is hoping to determine whether Imfinzi and tremelimumab, or just Imfinzi alone, is more effective with surgery.
The trial at Dana-Farber is designed for pleural mesothelioma patients who are not surgical candidates.
“These drugs have proven to be very effective in solid tumors,” said Dr. Bryan Burt, thoracic surgeon and lead investigator at Baylor. “This will allow us to gain a much deeper understanding for how these drugs work with mesothelioma.”
Impressive Results in Italian Study
The median overall survival in the Italian study of the two-drug combination was 16.6 months.
The one-year survival rate was 62 percent. Almost a third of the patients achieved a long-lasting objective response.
Twenty-six of the 40 patients in the trial displayed immune-related disease control with a median duration of 10.6 months.
All measures exceeded typical results with standard chemotherapy.
Each of the two study drugs had been used individually in previous mesothelioma clinical trials, but neither worked as well as they did in combination, which produced a synergistic effect.
Imfinzi works by blocking a specific protein that cancer cells often produce to stop a person’s own immune system from attacking the tumor.
Tremelimumab works by blocking a receptor on the immune cells that normally stops an immune attack.
Patients in the study were treated four times, receiving tremelimumab and Imfinzi through an IV once a month.
That was followed by maintenance Imfinzi alone, as necessary.
Other Immunotherapy Combinations Working Well
The two-drug combination has proven effective with other cancers, including melanoma.
“This is the first study that has demonstrated the activity of this combination in first- and second-line mesothelioma patients,” Calabro said. “As we know, standard chemotherapy is unsatisfactory.”
Calabro also pointed to another immunotherapy combination — Opdivo (nivolumab) and Yervoy (ipilimumab) — that works in similar ways and is now in a phase III study.
“If results of that study are positive, immunotherapy will become the new standard treatment for front-line mesothelioma patients,” she said. “It’s all very encouraging.”